Title |
Dimebon disappointment
|
---|---|
Published in |
Alzheimer's Research & Therapy, September 2010
|
DOI | 10.1186/alzrt49 |
Pubmed ID | |
Authors |
Roy W Jones |
Abstract |
Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this study there were improvements over 6 months in all endpoints (cognitive, global, daily function and behaviour), with continuing improvement at 12 months in cognition and daily function. A more recent multinational phase 3 study, however, showed no improvements whatsoever and no difference between the two drug-treated groups and the placebo group. Of note, there was little deterioration in any of the groups after 6 months in contrast to the placebo group in the phase 2 study. The potential reasons for these disappointing results are discussed, as well as the implication for dimebon and drug treatment in Alzheimer's disease. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 4 | 15% |
Researcher | 4 | 15% |
Other | 4 | 15% |
Student > Ph. D. Student | 3 | 12% |
Student > Doctoral Student | 2 | 8% |
Other | 7 | 27% |
Unknown | 2 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 5 | 19% |
Agricultural and Biological Sciences | 5 | 19% |
Biochemistry, Genetics and Molecular Biology | 3 | 12% |
Medicine and Dentistry | 3 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Other | 4 | 15% |
Unknown | 4 | 15% |